News Medical on MSN10d
High discontinuation rates of GLP-1 agonists found among patients with obesity
Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...
News Medical on MSN11d
Prescription trends for obesity medications surge, tied to growing interest in GLP-1 drugs
Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...
GlobalData on MSN8d
Palatin concludes Phase II trial of combination therapy for obesity
Palatin Technologies has completed its Phase II study, BMT-801, evaluating the joint administration of melanocortin 4 ...
Business Insider15d
New Truveta study highlights patterns of discontinuation and reinitiation of GLP-1 RA medications
Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications, including semaglutide and the dual GLP-1 RA/gastric inhibitory polypeptide (GIP) medication tirzepatide, have gained widespread ...
Amgen says Phase 1 AMG 513 obesity study placed on clinical hold by FDA
Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS
Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.
Yahoo Finance8d
Palatin concludes Phase II trial of combination therapy for obesity
a glucagon-like peptide-1 (GLP-1)/gastric inhibitory polypeptide (GIP), to treat obesity. The final output collection and quality control will be completed soon, with top-line data anticipated ...
Morningstar15d
New Truveta study highlights patterns of discontinuation and reinitiation of GLP-1 RA medications
Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications, including semaglutide and the dual GLP-1 RA/gastric inhibitory polypeptide (GIP) medication tirzepatide, have gained ...